Pharsight

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8410103	VIIV HLTHCARE	(3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent	Apr, 2026 (3 years from now)
US10927129	VIIV HLTHCARE	N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity	Apr, 2026 (3 years from now)
CN101346376A	VIIV HLTHCARE	Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase	Jul, 2011 (11 years ago)
CN101212903B	VIIV HLTHCARE	Polycyclic Carbamoyl Pyridone Derivative Having Hiv Integrase Inhibitory Activity	Apr, 2026 (3 years from now)
CN101212903A	VIIV HLTHCARE	Polycyclic Carbamoyl Pyridone Derivative Having Hiv Integrase Inhibitory Activity	Apr, 2026 (3 years from now)
EP1852434A1	VIIV HLTHCARE	Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibiting Activity	Feb, 2026 (3 years from now)
EP1852434B1	VIIV HLTHCARE	Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibiting Activity	Feb, 2026 (3 years from now)
EP1852434A4	VIIV HLTHCARE	Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibiting Activity	Feb, 2026 (3 years from now)
EP2527007B1	VIIV HLTHCARE	Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity	Apr, 2026 (3 years from now)
EP3372281A1	VIIV HLTHCARE	Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity	Apr, 2026 (3 years from now)
EP3187225B1	VIIV HLTHCARE	Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity	Apr, 2026 (3 years from now)
EP3045206A1	VIIV HLTHCARE	Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity	Apr, 2026 (3 years from now)
EP3284520A1	VIIV HLTHCARE	Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity	Apr, 2026 (3 years from now)
EP3284520B1	VIIV HLTHCARE	Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity	Apr, 2026 (3 years from now)
EP3187225A1	VIIV HLTHCARE	Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity	Apr, 2026 (3 years from now)
EP3372281B1	VIIV HLTHCARE	Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity	Apr, 2026 (3 years from now)
EP3045206B1	VIIV HLTHCARE	Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity	Apr, 2026 (3 years from now)
EP2527007A1	VIIV HLTHCARE	Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity	Apr, 2026 (3 years from now)
EP1874117B8	VIIV HLTHCARE	Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity	Apr, 2026 (3 years from now)
EP1874117A4	VIIV HLTHCARE	Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity	Apr, 2026 (3 years from now)
EP2465580A1	VIIV HLTHCARE	Polycyclic Carbamoylpyridone Derivatives Having Hiv Integrase Inhibitory Activity	Apr, 2026 (3 years from now)
EP1874117A1	VIIV HLTHCARE	Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity	Apr, 2026 (3 years from now)
EP1874117B1	VIIV HLTHCARE	Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity	Apr, 2026 (3 years from now)
EP2465580B1	VIIV HLTHCARE	Polycyclic Carbamoylpyridone Derivatives Having Hiv Integrase Inhibitory Activity	Apr, 2026 (3 years from now)
EP1950212B1	VIIV HLTHCARE	Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase	Oct, 2026 (4 years from now)
EP1950212A4	VIIV HLTHCARE	Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase	Oct, 2026 (4 years from now)
EP1950212A1	VIIV HLTHCARE	Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase	Oct, 2026 (4 years from now)

Drugs and Companies using CABOTEGRAVIR SODIUM ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 30MG BASE	TABLET;ORAL	Prescription

Pharsight

Drug name - Vocabria

availability in other generic markets.

Click on the highlighted region to filter.

Pharsight

Drug name - Vocabria

availability in other generic markets. Click on the highlighted region to filter.

availability in other generic markets.

Click on the highlighted region to filter.